la Fougere

@uni-tuebingen.de

Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tubingen
Eberhard Karls Universitat Tubingen

la Fougere


               Download Compact PDF  
https://researchid.co/ralafoc1
308

Scopus Publications

17439

Scholar Citations

66

Scholar h-index

216

Scholar i10-index

Scopus Publications

  • Continuous bed motion versus step-and-shoot acquisition in LAFOV PET/CT: insights from multi-phantom and patient studies
    P. M. Linder, W. Lan, E. Calderón, I. Rausch, C. la Fougère, et al.
    Ejnmmi Physics, 2026
    Background Continuous bed motion (CBM) allows flexible extension of the scan range compared to conventional step‑and‑shoot (S&S) acquisition but has not yet been evaluated in long axial field‑of‑view (LAFOV) PET/CT. This study systematically assessed the impact of CBM on image quality, noise, and quantitative performance in the Biograph Vision Quadra LAFOV PET/CT using multi‑phantom and patient scans compared to S&S. Methods A uniform tube phantom and a NEMA IEC phantom, positioned centrally and off-centre, were scanned across bed speeds (2.8–50 mm/s), sensitivity modes and scan ranges (106 and 150 cm) to evaluate image uniformity, axial count profiles, noise and contrast recovery coefficients (CRC). Ten oncological patients receiving [ 18 F]PSMA-1007 or [ 18 F]FDG underwent sequential CBM (2.8 mm/s, 378 s) and S&S (300 s) scans. Image noise, net true counts, and liver and lesion SUV values were compared using paired statistics and Bland–Altman analysis, along with PSMA expression scores. Results For comparable count statistics and image noise, CBM required a prolonged acquisition (378 s) to match the S&S (300 s) protocol, resulting in comparable image quality for phantoms and patients. CRC and image uniformity were preserved across all evaluated conditions, even at the FOV’s axial edge (50.5 cm) for 8.4 mm/s (22 mm sphere: CRC 76% S&S vs. 71% CBM). In patient scans, minor differences in axial count profiles, net true counts, and SUV values (SUV mean bias − 0.1 (liver) and − 0.8 (lesions)) did not affect clinical scores. Conclusions The prolonged CBM protocol provides image quality and quantitative performance comparable to S&S in LAFOV PET/CT. While the reconstructed image range remains constrained by CT coverage, the patient scan comparison with 106 cm scan range, together with extended range phantom measurements, indicate that CBM can support scan range extension beyond 106 cm without compromising diagnostic accuracy.
  • Estimation of Future Patient Populations Eligible for Radioligand Therapies in the EU and the UK: A Modelling Study
    Uwe Holzwarth, Roberta Cirillo, Margarida Goulart, Diego Hernandez, Platon Peristeris, et al.
    Lancet Regional Health Europe, 2026
  • Exploring extended [18F]FDG kinetics in lymphoma with ultra-late LAFOV-PET/CT
    Matthias Weissinger, Stephan Ursprung, Johann Jacoby, Jonas Vogel, Eduardo Calderón, et al.
    European Journal of Nuclear Medicine and Molecular Imaging, 2026
    Purpose This prospective trial investigated extended [¹⁸F]FDG kinetics in lymphoma to provide in-vivo insights into glucose metabolism with potential relevance for staging and risk stratification. Methods Fifteen consecutive, treatment- naïve lymphoma patients (4 Hodgkin, 11 non-Hodgkin) underwent routine whole-body [ 18 F]FDG-PET/CT at 1 h post injection (p.i., injected activity 3.02 ± 0.34 MBq/kg) followed by additional Long Axial Field-Of-View (LAFOV)-PET/CT scans at 3 h and 6 h p.i. (Biograph Vision Quadra ® , Siemens Healthineers; acquisition 5/15/30 min). Standardised uptake values (SUV) of lymphoma, benign lymph nodes, organs and reference tissues were quantified and multi time-point kinetics were described using Retention Indices (RI) and linear/quadratic trajectory analyses. Image quality was rated by two blinded readers on a 5-point Likert scale. Results Image quality remained diagnostic in all datasets. Median Tumour-to-Background Ratio (TBR) increased significantly from 4.1 (1 h p.i.) to 12.5 (3 h p.i.) and 23.9 (6 h p.i.), p < 0.001. High-grade lymphoma exhibited an almost linear SUV rise, whereas low-grade entities followed a parabolic course, peaking at 3 h p.i. Benign lymph nodes demonstrated constant uptake (1 h: 0.9 ± 0.3, 3 h: 0.8 ± 0.5, 6 h: 0.8 ± 0.4). RIs showed a significant increase in [¹⁸F]FDG uptake over time in lymphoma, compared with a decline in benign lymph nodes (1–3 h p.i.: 19.4% vs. -14.4%, p < 0.001). Conclusion The LAFOV scanner enables high-quality [¹⁸F]FDG PET imaging for up to 6 h p.i., with a six-fold increase of TBR in ultra-late scans 6 h p.i. Extended [¹⁸F]FDG kinetic analysis differentiates high- and low-grade lymphomas from benign lymph nodes and reveals a significant decline in tracer uptake low-grade lymphomas between 3 and 6 h p.i. Trial registration DRKS00027307. Registered 26 November 2021.
  • Updated Procedure Guideline of the German Society of Nuclear Medicine for Amyloid Brain PET Imaging 30
    Henryk Barthel, Matthias Brendel, Nathalie Albert, Henning Boecker, Caroline Bouter, et al.
    Nuklearmedizin Nuclearmedicine, 2026
    Preamble This represents a substantial development of the guideline on the topic first published in 2016. The following notable points have been updated: the sections on background information; the clinical benefit of the method; the resulting differential diagnostic considerations; the outlook for possible future extensions of the indication spectrum; the quantitative analysis of the PET images; the embedding of the method in diagnostic pathways; and the relation to alternative biomarker methods such as amyloid measurement in CSF/blood.
  • Identification of genetic modifiers of autosomal dominant Alzheimer's disease: a genome-wide association study
    Maulikkumar Patel, Wei Feng, Nicole S Mckay, Peter R Millar, Menghan Liu, et al.
    Lancet Neurology, 2026
  • The PET tracer [¹¹C]MODAG-005 targets alpha-synuclein aggregates in the brain
    Ran Sing Saw, Sabrina Haas, Felix Schmidt, Sergey Ryazanov, Andrei Leonov, et al.
    Science Translational Medicine, 2026
    Synucleinopathies are neurodegenerative diseases characterized by the presence of brain inclusions containing the pathologically aggregated protein α-synuclein. The development of a positron emission tomography tracer to detect aggregates of misfolded α-synuclein could revolutionize early diagnosis, disease monitoring, and the evaluation of therapeutic efficacy. Here, we present the development, preclinical validation, and first-in-human evaluation of [ 11 C]MODAG-005. In vitro binding experiments demonstrated subnanomolar binding affinity to recombinant α-synuclein fibrils and to α-synuclein inclusions in human brain tissue. Specific binding in multiple system atrophy (MSA) brain tissue was detected using autoradiography and microautoradiography and was validated through immunostaining. In vivo, [ 11 C]MODAG-005 showed good brain penetration, rapid clearance from brain tissue, and low metabolite formation in rodents and nonhuman primates. In addition, a pronounced binding and a good signal-to-noise ratio were achieved in an α-synuclein fibril–injected rat model and in an α-synuclein (A30P) transgenic mouse model in correlation to the pathological load. To validate the potential of [ 11 C]MODAG-005 for therapeutic development, we showed target engagement of the drug candidate anle138b in the brain tissues from α-synuclein (A30P) mice and patients with multiple system atrophy as well as in vivo in α-synuclein fibril–injected rats. Last, first-in-human imaging demonstrated [ 11 C]MODAG-005 binding in brain regions affected by α-synuclein pathology in patients with clinically established MSA cerebellar type, MSA cerebellar and parkinsonian type, and Parkinson’s disease.
  • PET-imaging derived prognostic factors for prostate cancer patients with visceral metastases receiving [177Lu]Lu-PSMA radiopharmaceutical therapy (RPT)
    Magdalena Sophie Späth, Helmut Dittmann, Richard Spallek, Eduardo Calderón, Jonas Mück, et al.
    European Journal of Nuclear Medicine and Molecular Imaging, 2026
  • The German Cancer Consortium (DKTK) multi-center prospective phase 1/2 68Ga-PSMA-11 PET-imaging trial in newly-diagnosed high-risk prostate cancer: Safety and diagnostic accuracy compared to histopathology and their impact on patient management
    Frederik L. Giesel, Stefan A. Koerber, Boris Hadaschik, Selina Kiefer, Sarah Schwarzenboeck, et al.
    European Journal of Nuclear Medicine and Molecular Imaging, 2026
    Purpose Clinically accurate detection of prostate cancer (PCa) metastases is crucial for management of high-risk PCa patients scheduled for radical prostatectomy. We determine the safety and diagnostic accuracy of pre-operative 68 Ga-PSMA-11 PET/CT imaging in newly diagnosed high-risk PCa and assess its impact on patient management. Methods Investigator-initiated prospective multi-center multinational single-arm open-label phase 1/2 imaging trial (EuRadCT 2016–001815-19). Patients with high-risk PCa scheduled for prostatectomy were enrolled at 9 institutions in Germany, Austria, and Switzerland to undergo 68 Ga-PSMA-11 PET/CT for primary staging. The primary objectives were the evaluation of 68 Ga-PSMA-11 PET/CT imaging to detect the primary tumor and lymph node disease and safety assessment. Secondary objectives included detection of distant metastases, correlation of 68 Ga-PSMA-11 uptake with Gleason Score, and determining the impact on clinical management. Impact of pre-operative 68 Ga-PSMA-11 PET/CT imaging on target volume definition for radiation therapy was assessed. Results 173 patients underwent 68 Ga-PSMA-11 PET/CT for primary staging. Histopathologic correlation was available in 139 patients (imaging dataset), with lymph node metastases in 55 patients (39.6%). 20 treatment-emergent AEs unrelated to the test item were reported in 14 of 173 (8.1%) patients and no SAE occurred. On a per-patient basis, sensitivity of 68 Ga-PSMA-11 PET for local disease was 0.971 (95% CI, 0.928–0.992). Sensitivity, specificity, PPV, NPV and accuracy to detect local lymph node disease on a per-patient basis were 0.400 (95% CI 0.271–0.529), 0.988 (95%CI 0.965–1.000), 0.957 (95% CI 0.873–1.000), 0.716 (95% CI 0.633–0.798) and 0.755 (95% CI 0.684–0.827), respectively. Considering the intrinsic PET resolution of 3–5 mm, the exclusion of lesions smaller than 3 or 5 mm on histopathology from the analysis led to increased sensitivity of 56.4% and 69.0%, respectively. Median SUVpeak of local disease was 6.4 (range 1.7–13.6), 8.4 (range 2.3–39.4), 10.7 (range 5.6–23.0), and 13.4 (range 3.8–56.9) for Gleason Score 7a, 7b, 8 and 9, respectively. Based on the results of 68 Ga-PSMA-11 PET/CT, surgical intervention was canceled in 23 patients (13.2%). 68 Ga-PSMA-11 PET/CT resulted in a change of target volume delineation for radiation therapy planning in 29 patients (20.9%). Conclusion In high-risk primary PCa, 68 Ga-PSMA-11 is safe and effective in local staging, resulting in changes in both surgical and radiation management. Moreover, 68 Ga-PSMA-11 uptake is positively correlated with tumor grade and its efficacy is dependent on the size of nodal lesions. 68 Ga-PSMA-11 PET/CT will be highly impactful in the management of newly diagnosed high risk prostate cancer patients. Funding The study was funded by the German Cancer Consortium (DKTK).
  • Longitudinal subcortical volume changes and their correlations with multiple PET and fluid biomarkers in dominantly inherited Alzheimer’s disease
    IL Han Choo, Hoyoung Park, Brian A. Gordon, Randall J. Bateman, Randall Bateman, et al.
    Journal of Prevention of Alzheimer S Disease, 2026
  • AutoPET Challenge on Fully Automated Lesion Segmentation in Oncologic PET/CT Imaging, Part 2: Domain Generalization
    Jakob Dexl, Sergios Gatidis, Marcel Früh, Katharina Jeblick, Andreas Mittermeier, et al.
    Journal of Nuclear Medicine Official Publication Society of Nuclear Medicine, 2026
  • Primary Renal Neuroendocrine Tumor: Diagnostic Challenges in a Rare Entity—A Case Report
    Raphaela D. Lewetag, Katharina Kluthe, Nils F. Trautwein, Ulrich M. Lauer, Christian la Fougère, et al.
    Current Oncology, 2026
  • A framework for using DNA methylation-based modelling for the clinical management of cranial meningioma
    Alexander P Landry, Justin Z Wang, Vikas Patil, Andrew Ajisebutu, Chloe Gui, et al.
    Neuro Oncology, 2026
  • Excellent Response to Combined 223Ra-dichloride and Enzalutamide After Failure of 177Lu-PSMA Radioligand Therapy
    Eduardo Calderón, Magdalena Sophie Späth, Moritz Maas, Christian la Fougère, Nils F. Trautwein
    Clinical Nuclear Medicine, 2026
  • Beyond image quality: Patient experience with long-axial field-of-view and standard PET/CT systems
    Daniel Sauerbrunn, Norbert Schäffeler, Julia Sekler, Johann Jacoby, Konstantin Nikolaou, et al.
    European Journal of Nuclear Medicine and Molecular Imaging, 2026
  • The inflammatory fingerprint reveals immune cell populations associated with disease activity in cardiac sarcoidosis
    Tobias Harm, Stella E. Autenrieth, Katharina Mezger, Anne-Katrin Rohlfing, Helmut Dittman, et al.
    Clinical Research in Cardiology, 2026
  • AutoPET Challenge on Fully Automated Lesion Segmentation in Oncologic PET/CT Imaging, Part 2: Domain Generalization
    Zhuona Rong, Hongjin Liu, Xia Teng, Lin Chen, Yanlun Gu, et al.
    Journal of Nuclear Medicine, 2026
  • Brain volume trajectories in Down syndrome and autosomal dominant Alzheimer's disease
    James T. Kennedy, Julie K. Wisch, Anna H. Boerwinkle, Peter R. Millar, Nicole S. McKay, et al.
    Alzheimer S and Dementia, 2026
  • Cortical asymmetry in autosomal dominant Alzheimer’s disease progression
    Agnès Pérez-Millan, Neus Falgàs, Beatriz Bosch, Sergi Borrego-Écija, Anna Antonell, et al.
    Brain Communications, 2026
  • Feasibility of in vivo small animal imag ing using a clinical total-body PET/CT system
    Julia G. Mannheim, Wenhong Lan, Maurizio Conti, Franziska Siedler, Marcel A. Krueger, et al.
    Ejnmmi Physics, 2025
  • Cardiac Metastases in Neuroendocrine Neoplasms: A Single-Center Experience of Clinical Characteristics and Outcomes
    Raphaela D. Lewetag, Nils F. Trautwein, Monika Zdanyte, Jonas Mück, Patrick Krumm, et al.
    Cancers, 2025
  • A digital twin of the Biograph Vision Quadra long axial field of view PET/CT: Monte Carlo simulation and image reconstruction framework
    Christian M. Pommranz, Ezzat A. Elmoujarkach, Wenhong Lan, Jorge Cabello, Pia M. Linder, et al.
    Ejnmmi Physics, 2025
  • Low-activity [18F]-somatostatin receptor (SSTR) imaging using [18F]SiTATE on a long axial field-of-view PET/CT scanner
    Nils F. Trautwein, Eduardo Calderón, Pia M. Linder, Gerald Reischl, Philippe Driessen, et al.
    Ejnmmi Physics, 2025
  • Cross-Sectional FDG in Down Syndrome and Autosomal Dominant Alzheimer's Disease
    Omar Abdelmoity, Julie K. Wisch, James T. Kennedy, Manu Goyal, Andrei Vlassenko, et al.
    Annals of Neurology, 2025
  • PET/CT-based target volume definition in involved-site radiotherapy for treatment of early-stage nodal follicular lymphoma
    Antje Wark, Ji-Young Kim, Elena Mavriopoulou, Christian la Fougère, Thomas Wiegel, et al.
    Strahlentherapie Und Onkologie, 2025
  • Impact of the maximum ring difference on image quality and noise characteristics of a total-body PET/CT scanner
    F.P. Schmidt, J.G. Mannheim, P.M. Linder, P. Will, L.S. Kiefer, et al.
    Zeitschrift Fur Medizinische Physik, 2025

RECENT SCHOLAR PUBLICATIONS

  • Updated Procedure Guideline of the German Society of Nuclear Medicine for Amyloid Brain PET Imaging 3.0
    H Barthel, M Brendel, N Albert, H Boecker, C Bouter, J Brumberg, ...
    Nuklearmedizin-NuclearMedicine 65 (03), 223-235 , 2026
    2026
  • Identification of genetic modifiers of autosomal dominant Alzheimer's disease: a genome-wide association study
    M Patel, W Feng, NS Mckay, PR Millar, M Liu, C Yang, A Cetin, ...
    The Lancet Neurology 25 (6), 581-590 , 2026
    2026
    Citations: 1
  • A longitudinal whole-body CT dataset with manually annotated tumor lesions
    S Gatidis, F Peisen, A Wagner, POM Choudja, A Othman, A Sanner, ...
    Scientific Data , 2026
    2026
  • The inflammatory fingerprint reveals immune cell populations associated with disease activity in cardiac sarcoidosis
    T Harm, SE Autenrieth, K Mezger, AK Rohlfing, H Dittman, C la Fougère, ...
    Clinical Research in Cardiology, 1-14 , 2026
    2026
  • The autoPET3 Challenge--Automated Lesion Segmentation in Whole-Body PET/CT-Multitracer Multicenter Generalization
    J Dexl, K Jeblick, A Mittermeier, B Schachtner, AT Stüber, J Topalis, ...
    arXiv preprint arXiv:2605.05775 , 2026
    2026
  • Continuous bed motion versus step-and-shoot acquisition in LAFOV PET/CT: insights from multi-phantom and patient studies
    PM Linder, W Lan, E Calderón, I Rausch, C la Fougère, FP Schmidt
    EJNMMI Physics , 2026
    2026
  • Beyond image quality: Patient experience with long-axial field-of-view and standard PET/CT systems
    D Sauerbrunn, N Schäffeler, J Sekler, J Jacoby, K Nikolaou, C la Fougère, ...
    European Journal of Nuclear Medicine and Molecular Imaging, 1-15 , 2026
    2026
  • Characterization of metabolic tumor kinetics in head and neck squamous cell carcinoma using ultra-late [18F] FDG PET imaging
    E Calderón, P Pelz, J von Fraunberg, S Böke, M Weissinger, H Dittmann, ...
    Nuklearmedizin-NuclearMedicine 65 (02), P24 , 2026
    2026
  • Real-world experience with lutetium (177Lu) vipivotide tetraxetan (177Lu-PSMA-617) in metastatic castration resistant prostate cancer (mCRPC): Results from the first interim …
    K Herrmann, C la Fougère, T Winkens, A Buck, F Zengerling
    Nuklearmedizin-NuclearMedicine 65 (02), V77 , 2026
    2026
  • Prognostic value of [64Cu] GD2 PET beyond [18F] FDG PET in sarcoma patients
    N Trautwein, H Dittmann, S Kailayangiri, CKW Deinzer, G Reischl, P Lang, ...
    Nuklearmedizin-NuclearMedicine 65 (02), V8 , 2026
    2026
  • PET-basierte prognostische Faktoren für mCRPC Patienten mit viszeralen Metastasen unter [177Lu] Lu-PSMA RLT
    M Späth, H Dittmann, R Spallek, E Calderon, J Mück, A Brendlin, ...
    Nuklearmedizin-NuclearMedicine 65 (02), P65 , 2026
    2026
  • Einsatz Somatostatinrezeptor (SSTR)-gerichteter Radioligandentherapie (RLT) bei Patienten mit pankreatischen neuroendokrinen Tumoren (panNET) in Deutschland
    M Schmidt, N Trautwein, C la Fougère, B Kreppel, M Essler, C Däubler, ...
    Nuklearmedizin-NuclearMedicine 65 (02), V38 , 2026
    2026
  • Histologische ex vivo Validierung von [18F] SiTATE für SSTR-PET bei Meningeomen
    R Gerdes, J Schittenhelm, S Singer, B Bender, C la Fougère, N Trautwein
    Nuklearmedizin-NuclearMedicine 65 (02), P20 , 2026
    2026
  • Longitudinal subcortical volume changes and their correlations with multiple PET and fluid biomarkers in dominantly inherited Alzheimer’s disease
    ILH Choo, H Park, BA Gordon, RJ Bateman, R Bateman, AJ Daniels, ...
    The Journal of Prevention of Alzheimer's Disease 13 (4), 100513 , 2026
    2026
  • The German Cancer Consortium (DKTK) multi-center prospective phase 1/2 68Ga-PSMA-11 PET-imaging trial in newly-diagnosed high-risk prostate cancer: Safety and diagnostic …
    FL Giesel, SA Koerber, B Hadaschik, S Kiefer, S Schwarzenboeck, ...
    European journal of nuclear medicine and molecular imaging 53 (5), 2994-3006 , 2026
    2026
  • AutoPET challenge on fully automated lesion segmentation in oncologic PET/CT imaging, part 2: domain generalization
    J Dexl, S Gatidis, M Früh, K Jeblick, A Mittermeier, AT Stüber, ...
    Journal of Nuclear Medicine 67 (3), 481-488 , 2026
    2026
    Citations: 5
  • Exploring extended [ 18 F]FDG kinetics in lymphoma with ultra-late LAFOV-PET/CT
    M Weissinger, S Ursprung, J Jacoby, J Vogel, E Calderón, B Gückel, ...
    European Journal of Nuclear Medicine and Molecular Imaging, 1-12 , 2026
    2026
  • Primary Renal Neuroendocrine Tumor: Diagnostic Challenges in a Rare Entity—A Case Report
    RD Lewetag, K Kluthe, NF Trautwein, UM Lauer, C la Fougère, B Sipos, ...
    Current Oncology 33 (2), 105 , 2026
    2026
  • Advancing Automated Lesion Segmentation Toward Clinical Integration in Oncologic PET/CT
    POM Choudja, J Dexl, M Frueh, K Jeblick, A Mittermeier, AT Stueber, ...
    ONCOLOGY RESEARCH AND TREATMENT 49, 237-237 , 2026
    2026
  • PET-imaging derived prognostic factors for prostate cancer patients with visceral metastases receiving [177Lu] Lu-PSMA radiopharmaceutical therapy (RPT)
    MS Späth, H Dittmann, R Spallek, E Calderón, J Mück, A Brendlin, ...
    European Journal of Nuclear Medicine and Molecular Imaging, 1-8 , 2026
    2026

MOST CITED SCHOLAR PUBLICATIONS

  • Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas
    NL Albert, M Weller, B Suchorska, N Galldiks, R Soffietti, MM Kim, ...
    Neuro-oncology 18 (9), 1199-1208 , 2016
    2016
    Citations: 877
  • Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study
    BA Gordon, TM Blazey, Y Su, A Hari-Raj, A Dincer, S Flores, ...
    The Lancet Neurology 17 (3), 241-250 , 2018
    2018
    Citations: 740
  • Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [ 18 F]FDG: version …
    I Law, NL Albert, J Arbizu, R Boellaard, A Drzezga, N Galldiks, ...
    European journal of nuclear medicine and molecular imaging 46 (3), 540-557 , 2019
    2019
    Citations: 617
  • Real versus imagined locomotion: a [18F]-FDG PET-fMRI comparison
    C La Fougere, A Zwergal, A Rominger, S Förster, G Fesl, M Dieterich, ...
    Neuroimage 50 (4), 1589-1598 , 2010
    2010
    Citations: 532
  • Attention deficit hyperactivity disorder: binding of [ 99m Tc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment
    S Dresel, J Krause, KH Krause, C LaFougere, K Brinkbäumer, HF Kung, ...
    European journal of nuclear medicine 27 (10), 1518-1524 , 2000
    2000
    Citations: 397
  • A whole-body FDG-PET/CT dataset with manually annotated tumor lesions
    S Gatidis, T Hepp, M Früh, C La Fougère, K Nikolaou, C Pfannenberg, ...
    Scientific Data 9 (1), 601 , 2022
    2022
    Citations: 395
  • Molecular imaging of gliomas with PET: opportunities and limitations
    C la Fougere, B Suchorska, P Bartenstein, FW Kreth, JC Tonn
    Neuro-oncology 13 (8), 806-819 , 2011
    2011
    Citations: 374
  • PET and SPECT in epilepsy: a critical review
    C La Fougère, A Rominger, S Förster, J Geisler, P Bartenstein
    Epilepsy & Behavior 15 (1), 50-55 , 2009
    2009
    Citations: 333
  • Comparison of 68 Ga-labelled PSMA-11 and 11 C-choline in the detection of prostate cancer metastases by PET/CT
    J Schwenck, H Rempp, G Reischl, S Kruck, A Stenzl, K Nikolaou, ...
    European journal of nuclear medicine and molecular imaging 44 (1), 92-101 , 2017
    2017
    Citations: 325
  • Advances in PET imaging of cancer
    J Schwenck, D Sonanini, JM Cotton, HG Rammensee, C la Fougère, ...
    Nature Reviews Cancer 23 (7), 474-490 , 2023
    2023
    Citations: 314
  • DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management
    F Nassiri, Y Mamatjan, S Suppiah, JH Badhiwala, S Mansouri, S Karimi, ...
    Neuro-oncology 21 (7), 901-910 , 2019
    2019
    Citations: 284
  • Hot spots in dynamic18FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas
    M Kunz, N Thon, S Eigenbrod, C Hartmann, R Egensperger, J Herms, ...
    Neuro-oncology 13 (3), 307 , 2011
    2011
    Citations: 284
  • [ 18 F]-fluoro-ethyl- l -tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma
    M Hutterer, M Nowosielski, D Putzer, NL Jansen, M Seiz, M Schocke, ...
    Neuro-oncology 15 (3), 341-351 , 2013
    2013
    Citations: 273
  • Two decades of SPECT/CT–the coming of age of a technology: an updated review of literature evidence
    O Israel, O Pellet, L Biassoni, D De Palma, E Estrada-Lobato, ...
    European journal of nuclear medicine and molecular imaging 46 (10), 1990-2012 , 2019
    2019
    Citations: 264
  • The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder
    KH Krause, SH Dresel, J Krause, C la Fougere, M Ackenheil
    Neuroscience & Biobehavioral Reviews 27 (7), 605-613 , 2003
    2003
    Citations: 262
  • Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases
    LA Hoffmann, S Jarius, HL Pellkofer, M Schueller, M Krumbholz, F Koenig, ...
    Journal of Neurology, Neurosurgery & Psychiatry 79 (7), 767-773 , 2008
    2008
    Citations: 231
  • Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial
    U Nestle, T Schimek-Jasch, S Kremp, A Schaefer-Schuler, M Mix, ...
    The Lancet Oncology 21 (4), 581-592 , 2020
    2020
    Citations: 230
  • Imaging and diagnostic advances for intracranial meningiomas
    RY Huang, WL Bi, B Griffith, TJ Kaufmann, C la Fougère, NO Schmidt, ...
    Neuro-oncology 21 (Supplement_1), i44-i61 , 2019
    2019
    Citations: 227
  • MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET?
    NL Jansen, V Graute, L Armbruster, B Suchorska, J Lutz, S Eigenbrod, ...
    European journal of nuclear medicine and molecular imaging 39 (6), 1021-1029 , 2012
    2012
    Citations: 220
  • Biological tumor volume in 18 FET-PET before radiochemotherapy correlates with survival in GBM
    B Suchorska, NL Jansen, J Linn, H Kretzschmar, H Janssen, S Eigenbrod, ...
    Neurology 84 (7), 710-719 , 2015
    2015
    Citations: 210